Travere Therapeutics Enters Licensing Agreement Worth up to $1.1 Billion with Everest Medicines
U.S.-based biotech company Travere Therapeutics has entered into a licensing and collaboration agreement worth up to $1.1 billion with China's Everest Medicines, signaling continued cross-border deal-making in the biopharma sector.
Tickers: $TVTX